INF39 is primarily utilized in research settings as a potent and selective inhibitor of the NLRP3 inflammasome. This inflammasome is a key component of the innate immune system, and its dysregulation is implicated in various inflammatory diseases, including autoimmune disorders, neurodegenerative conditions, and metabolic syndromes. By inhibiting NLRP3, INF39 helps researchers study the mechanisms underlying these diseases and explore potential therapeutic strategies. Its application is particularly valuable in preclinical studies aimed at developing treatments for conditions like Alzheimer's disease, rheumatoid arthritis, and type 2 diabetes, where NLRP3 activation plays a critical role. Additionally, INF39 is used in cellular and animal models to dissect the signaling pathways associated with inflammation and to evaluate the efficacy of anti-inflammatory interventions.